Published in BMC Pulm Med on January 10, 2017
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med (2002) 12.95
Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol (2005) 10.99
Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med (2004) 7.12
Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA (2013) 4.17
Complex chronic comorbidities of COPD. Eur Respir J (2008) 3.84
Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest (2011) 3.72
Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 3.54
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol (2009) 3.32
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J (2005) 2.93
Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med (2007) 2.93
Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail (2009) 2.51
Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax (2011) 2.39
Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol (2003) 2.34
Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax (2007) 2.05
A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest (2009) 1.99
Utility of N-terminal pro B-type natriuretic peptide and mean platelet volume in differentiating congestive heart failure from chronic obstructive pulmonary disease. Int J Cardiol (2013) 1.99
Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol (2006) 1.91
N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation (2005) 1.86
NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J (2006) 1.81
Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.77
Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med (2006) 1.68
Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol (2014) 1.67
The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest (2011) 1.64
Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J (2004) 1.62
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol (2005) 1.57
Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation (2003) 1.38
Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest (2008) 1.20
Development of the RTI item bank on risk of bias and precision of observational studies. J Clin Epidemiol (2011) 1.12
Unrecognised ventricular dysfunction in COPD. Eur Respir J (2011) 1.06
Natriuretic peptides, respiratory disease, and the right heart. Chest (2004) 1.05
Prognostic value of cardiac troponin I in patients with COPD acute exacerbation. Neth J Med (2009) 1.03
The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease. J Int Med Res (2005) 1.02
Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med (1999) 0.99
Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration (1997) 0.99
Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest (2001) 0.98
Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail (2007) 0.98
Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir Med (2009) 0.97
High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med (2009) 0.97
The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ (2015) 0.95
NT-proBNP independently predicts long term mortality after acute exacerbation of COPD - a prospective cohort study. Respir Res (2012) 0.94
Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med (2007) 0.94
Biomarker Development for Chronic Obstructive Pulmonary Disease. From Discovery to Clinical Implementation. Am J Respir Crit Care Med (2015) 0.92
Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease. Int J Cardiol (2012) 0.89
The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Card Fail (2005) 0.89
Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One (2014) 0.89
Plasma endothelin-1 level in chronic obstructive pulmonary disease: relationship with natriuretic peptide. Respiration (1999) 0.88
Prognostic utility of NT-proBNP in acute exacerbations of chronic pulmonary diseases. Eur J Intern Med (2011) 0.86
Left ventricular hypertrophy in COPD without hypoxemia: the elephant in the room? Chest (2013) 0.85
Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease. Swiss Med Wkly (2011) 0.85
High Prevalence of Left Ventricle Diastolic Dysfunction in Severe COPD Associated with A Low Exercise Capacity: A Cross-Sectional Study. PLoS One (2013) 0.84
Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease. Lung (2012) 0.84
Survival experience of the population needing hospital treatment for asthma or COPD at age 50-54 years. Respir Med (1998) 0.84
Predicting mortality and hospital admission in patients with COPD: significance of NT pro-BNP, clinical and echocardiographic assessment. J Cardiovasc Med (Hagerstown) (2011) 0.83
Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD. Eur J Clin Invest (2013) 0.83
N-terminal proB-type natriuretic peptide levels aid the diagnosis of left ventricular dysfunction in patients with severe acute exacerbations of chronic obstructive pulmonary disease and renal dysfunction. Respirology (2012) 0.82
B-type natriuretic peptide levels in patients with COPD and normal right ventricular function. Adv Ther (2008) 0.80
The effects of hypoxia and hypercapnia on renal and heart function, haemodynamics and plasma hormone levels in stable COPD patients. Clin Respir J (2007) 0.80
Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2014) 0.79
Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clin Interv Aging (2013) 0.79
Echocardiographic screening for pulmonary hypertension in stable COPD out-patients and NT-proBNP as a rule-out test. COPD (2012) 0.78
Cardiac dysfunction and N-terminal pro-B-type natriuretic peptide in exacerbations of chronic obstructive pulmonary disease. Intern Med J (2013) 0.78
[Prognostic value of NT-proBNP in chronic pulmonary disease exacerbation]. Med Clin (Barc) (2010) 0.78
Left ventricular myocardial performance index predicts poor outcome during COPD exacerbation. Int J Cardiol (2014) 0.78
Diagnostic usefulness of B-type natriuretic peptide and functional consequences of muscle alterations in COPD and chronic heart failure. Chest (2006) 0.78
Effects of right ventricular dysfunction on exercise capacity and quality of life and associations with serum NT-proBNP levels in COPD: an observational study. Anadolu Kardiyol Derg (2014) 0.78
Assessment of the presence of occult myocardial infarction in chronic obstructive pulmonary disease using contrast-enhanced cardiac magnetic resonance imaging. Respiration (2009) 0.77
Cardiac response and N-terminal-pro-brain natriuretic peptide kinetics during exercise in patients with COPD. Respir Care (2011) 0.77
Predictive value of NT-proBNP in vascular surgery patients with COPD and normal left ventricular systolic function. COPD (2010) 0.77
Biomarker Development in COPD: Moving from P-Values to Products to Impact Patient Care. Chest (2016) 0.76
[Usefulness of NT-proBNP serum level in the diagnosis of dyspnea in COPD patients]. Pneumonol Alergol Pol (2013) 0.76
Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF: an observational study. PLoS One (2013) 0.76
Incidence of pulmonary embolism during COPD exacerbation. J Bras Pneumol (2014) 0.76
Serum levels of the soluble IL-1 receptor family member ST2 and right ventricular dysfunction. Biomark Med (2014) 0.76
[NT-proBNP in chronic obstructive pulmonary disease patients]. An Sist Sanit Navar (2009) 0.76
Diuretics, plasma brain natriuretic peptide and chronic obstructive pulmonary disease. Neth J Med (2007) 0.76
Utility of NT-proBNP for identifying LV failure in patients with acute exacerbation of chronic bronchitis. PLoS One (2013) 0.76
[Correlation between serum marker variations and pulmonary hypertension secondary to chronic obstructive pulmonary disease]. Nan Fang Yi Ke Da Xue Xue Bao (2013) 0.75